Tags

Type your tag names separated by a space and hit enter

Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus.
Metabolism 2010; 59(5):755-62M

Abstract

The objective of the study was to provide a comprehensive evaluation of chromium (Cr) supplementation on metabolic parameters in a cohort of type 2 diabetes mellitus subjects representing a wide phenotype range and to evaluate changes in "responders" and "nonresponders." After preintervention testing to assess glycemia, insulin sensitivity (assessed by euglycemic clamps), Cr status, and body composition, subjects were randomized in a double-blind fashion to placebo or 1000 microg Cr. A substudy was performed to evaluate 24-hour energy balance/substrate oxidation and myocellular/intrahepatic lipid content. There was not a consistent effect of Cr supplementation to improve insulin action across all phenotypes. Insulin sensitivity was negatively correlated to soleus and tibialis muscle intramyocellular lipids and intrahepatic lipid content. Myocellular lipids were significantly lower in subjects randomized to Cr. At preintervention, responders, defined as insulin sensitivity change from baseline of at least 10% or greater, had significantly lower insulin sensitivity and higher fasting glucose and A(1c) when compared with placebo and nonresponders, that is, insulin sensitivity change from baseline of less than 10%. Clinical response was significantly correlated (P < .001) to the baseline insulin sensitivity, fasting glucose, and A(1c). There was no difference in Cr status between responder and nonresponders. Clinical response to Cr is more likely in insulin-resistant subjects who have more elevated fasting glucose and A(1c) levels. Chromium may reduce myocellular lipids and enhance insulin sensitivity in subjects with type 2 diabetes mellitus who do respond clinically independent of effects on weight or hepatic glucose production. Thus, modulation of lipid metabolism by Cr in peripheral tissues may represent a novel mechanism of action.

Authors+Show Affiliations

Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA. cefaluwt@pbrc.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

20022616

Citation

Cefalu, William T., et al. "Characterization of the Metabolic and Physiologic Response to Chromium Supplementation in Subjects With Type 2 Diabetes Mellitus." Metabolism: Clinical and Experimental, vol. 59, no. 5, 2010, pp. 755-62.
Cefalu WT, Rood J, Pinsonat P, et al. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metab Clin Exp. 2010;59(5):755-62.
Cefalu, W. T., Rood, J., Pinsonat, P., Qin, J., Sereda, O., Levitan, L., ... Newcomer, B. (2010). Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 59(5), pp. 755-62. doi:10.1016/j.metabol.2009.09.023.
Cefalu WT, et al. Characterization of the Metabolic and Physiologic Response to Chromium Supplementation in Subjects With Type 2 Diabetes Mellitus. Metab Clin Exp. 2010;59(5):755-62. PubMed PMID: 20022616.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. AU - Cefalu,William T, AU - Rood,Jennifer, AU - Pinsonat,Patricia, AU - Qin,Jianhua, AU - Sereda,Olga, AU - Levitan,Lilian, AU - Anderson,Richard A, AU - Zhang,Xian H, AU - Martin,Julie M, AU - Martin,Corby K, AU - Wang,Zhong Q, AU - Newcomer,Bradley, Y1 - 2009/12/22/ PY - 2009/08/12/received PY - 2009/09/22/revised PY - 2009/09/25/accepted PY - 2009/12/22/entrez PY - 2009/12/22/pubmed PY - 2010/5/4/medline SP - 755 EP - 62 JF - Metabolism: clinical and experimental JO - Metab. Clin. Exp. VL - 59 IS - 5 N2 - The objective of the study was to provide a comprehensive evaluation of chromium (Cr) supplementation on metabolic parameters in a cohort of type 2 diabetes mellitus subjects representing a wide phenotype range and to evaluate changes in "responders" and "nonresponders." After preintervention testing to assess glycemia, insulin sensitivity (assessed by euglycemic clamps), Cr status, and body composition, subjects were randomized in a double-blind fashion to placebo or 1000 microg Cr. A substudy was performed to evaluate 24-hour energy balance/substrate oxidation and myocellular/intrahepatic lipid content. There was not a consistent effect of Cr supplementation to improve insulin action across all phenotypes. Insulin sensitivity was negatively correlated to soleus and tibialis muscle intramyocellular lipids and intrahepatic lipid content. Myocellular lipids were significantly lower in subjects randomized to Cr. At preintervention, responders, defined as insulin sensitivity change from baseline of at least 10% or greater, had significantly lower insulin sensitivity and higher fasting glucose and A(1c) when compared with placebo and nonresponders, that is, insulin sensitivity change from baseline of less than 10%. Clinical response was significantly correlated (P < .001) to the baseline insulin sensitivity, fasting glucose, and A(1c). There was no difference in Cr status between responder and nonresponders. Clinical response to Cr is more likely in insulin-resistant subjects who have more elevated fasting glucose and A(1c) levels. Chromium may reduce myocellular lipids and enhance insulin sensitivity in subjects with type 2 diabetes mellitus who do respond clinically independent of effects on weight or hepatic glucose production. Thus, modulation of lipid metabolism by Cr in peripheral tissues may represent a novel mechanism of action. SN - 1532-8600 UR - https://www.unboundmedicine.com/medline/citation/20022616/Characterization_of_the_metabolic_and_physiologic_response_to_chromium_supplementation_in_subjects_with_type_2_diabetes_mellitus_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(09)00413-2 DB - PRIME DP - Unbound Medicine ER -